NEWS & MEDIA
Featured
News
ZIRCON Phase 3 IND Submitted to the US FDA
Melbourne (Australia) – 24 December 2019. Telix Pharmaceuticals Limited is pleased to announce that it has submitted a Phase 3...
News
NDA Clinical Briefing Package Submitted to the US FDA
Melbourne (Australia) – 27 Dec 2019. Telix Pharmaceuticals Limited is pleased to announce that it has submitted a complete clinical...
News
TLX101 for Brain Cancer IPAX-1 Study Update
Melbourne (Australia) – 23 December 2019. Telix Pharmaceuticals has released an update on the progress of its TLX101 product being...
News
University of Melbourne collaboration with Telix receives Cancer Australia research grant
Melbourne (Australia) – 19th December 2019. Telix Pharmaceuticals Limited (ASX: TLX) is pleased to announce that Telix collaborator Professor Frédéric...
News
Telix Pharmaceuticals and ATONCO Partner for Bladder Cancer
Melbourne (Australia) and Nantes (France) – 16, Dec 2019. Telix Pharmaceuticals Limited and French company ATONCO S.A.S today announce that...
News
Webcast of CEO’s presentation to Jefferies 2019 London Healthcare Conference
Melbourne (Australia) – 25th November 2019. Telix Pharmaceuticals Limited has today announced that Group CEO, Dr Christian Behrenbruch, presented at...